Latest news, press releases, and SEC filings for Prelude Therapeutics Inc (PRLD) https://caymanjournal.com/stock/PRLD en-us Copyright 2026, Cayman Journal editorial@caymanjournal.com (Editorial Team) webmaster@caymanjournal.com (Web Master) Tue, 28 Apr 2026 00:03:41 GMT 60 https://caymanjournal.com/logo.png https://caymanjournal.com 144 144 # 📜 What This Document Is ✨ This document is an 8-K filing, which is a very important, mandatory filing used to announce major, unexpected events that happen *after* the company has already been publicly listed. Think of it like an urgent "Heads Up!" bulletin to investors. In simple terms, Prelud https://caymanjournal.com/stock/PRLD/sec-filing/0001193125-26-164510 https://caymanjournal.com/stock/PRLD/sec-filing/0001193125-26-164510 Tue, 21 Apr 2026 00:00:00 GMT SEC Filing # 📑 What This Document Is 📄 This filing is a material disclosure (an 8-K) announcing significant scientific progress for Prelude Therapeutics. It serves to update investors and the public on the impressive preclinical data generated for the company's lead drug candidate, PRT13722. 👉 Essentially, https://caymanjournal.com/stock/PRLD/sec-filing/0001193125-26-162620 https://caymanjournal.com/stock/PRLD/sec-filing/0001193125-26-162620 Mon, 20 Apr 2026 00:00:00 GMT SEC Filing